22nd Century Group, Inc, a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM research cigarettes for use in independent clinical studies.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryCannabis
SectorMedical
CIKN/A
Phone+1-716-2701523
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees82
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
22nd Century Group (NYSEAMERICAN:XXII) Frequently Asked Questions
What is 22nd Century Group's stock symbol?
22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII."
How were 22nd Century Group's earnings last quarter?
22nd Century Group Inc (NYSEAMERICAN:XXII) announced its quarterly earnings results on Wednesday, August, 7th. The biotechnology company reported ($0.06) EPS for the quarter. The biotechnology company earned $5.82 million during the quarter. View 22nd Century Group's Earnings History.
When is 22nd Century Group's next earnings date?
What price target have analysts set for XXII?
1 brokerages have issued 12 month price objectives for 22nd Century Group's shares. Their predictions range from $12.00 to $12.00. On average, they expect 22nd Century Group's stock price to reach $12.00 in the next year. This suggests a possible upside of 482.5% from the stock's current price. View Analyst Price Targets for 22nd Century Group.
What is the consensus analysts' recommendation for 22nd Century Group?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 22nd Century Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for 22nd Century Group.
What are Wall Street analysts saying about 22nd Century Group stock?
Here are some recent quotes from research analysts about 22nd Century Group stock:
- 1. According to Zacks Investment Research, "22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. " (10/12/2019)
- 2. Chardan Capital analysts commented, "We expect the Q1 rate to continue over the coming quarters. Cash at quarter end was $52 million, or almost 4 years of cash at the company’s current burn rate. However, investments in the hemp market, (see below), will lower the company’s cash balances modestly. Below the operating line, the company recognized a $3.0 million unrealized gain on the increase in value of its almost 1 million warrants of Aurora Cannabis. Aurora purchased the company’s stake in a combination of stock and warrants. All of the shares of Aurora were sold, but 22nd Century retained the warrants. In US dollars, Aurora trades at $8.60 per share and the exercise price of the warrants is $7.01 per share. The company is investing in the hemp market." (5/8/2019)
Has 22nd Century Group been receiving favorable news coverage?
Media headlines about XXII stock have been trending somewhat positive this week, according to InfoTrie. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. 22nd Century Group earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for 22nd Century Group.
Who are some of 22nd Century Group's key competitors?
Some companies that are related to 22nd Century Group include Mesoblast (MSB), Kodiak Sciences (KOD), BELLUS Health (BLU), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), Neptune Wellness Solutions (NEPT), Aprea Therapeutics (APRE), Starpharma (SPL), Oxford BioMedica (OXB), TELIX Pharmaceutical (TLX), Bellus Health (BLU), Theratechnologies (TH), ProMetic Life Sciences (PLI), Rafael (RFL) and Resverlogix (RVX).
What other stocks do shareholders of 22nd Century Group own?
Who are 22nd Century Group's key executives?
22nd Century Group's management team includes the folowing people:
- Mr. Henry Sicignano III, MBA, Pres, CEO & Director (Age 51)
- Mr. John T. Brodfuehrer, CFO & Treasurer (Age 61)
- Mr. Thomas L. James J.D., Esq., VP, Gen. Counsel & Sec. (Age 60)
- James Vail, Director of Communications
- Mr. James C. Morrison, Technical Advisor & Regulatory Affairs Consultant
How do I buy shares of 22nd Century Group?
Shares of XXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is 22nd Century Group's stock price today?
One share of XXII stock can currently be purchased for approximately $2.06.
How big of a company is 22nd Century Group?
What is 22nd Century Group's official website?
How can I contact 22nd Century Group?
22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523.
MarketBeat Community Rating for 22nd Century Group (NYSEAMERICAN XXII)
MarketBeat's community ratings are surveys of what our community members think about 22nd Century Group and other stocks. Vote "Outperform" if you believe XXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XXII will underperform the S&P 500 over the long term. You may vote once every thirty days.
